Sumatriptan

Introduction Overview

Generic Name

Sumatriptan

Brand Name

Imitrex, Onzetra Xsail, Zembrace, Symtouch, Tosymra, Alsuma

Dosage Form

Tablets, capsules, subcutaneous injection, nasal spray, nasal powder

Drug Class

Antimigraine agents (Selective serotonin 5-HT1B/1D receptor agonist)

Pharmacokinetics

Absorption:
Sumatriptan is rapidly absorbed following administration by oral, subcutaneous injection, and intranasal routes. Orally, peak plasma concentrations typically occur within 1 to 2 hours after ingestion, whereas subcutaneous injections produce a peak effect within approximately 10 minutes, providing quicker relief for acute migraine attacks. Intranasal formulations yield peak plasma concentrations within 1 to 1.5 hours. The absolute bioavailability after oral administration is approximately 14%, primarily due to significant first-pass hepatic metabolism. Absorption can be affected by factors such as gastrointestinal motility alterations during migraine attacks and food intake, which can slightly delay absorption but not reduce overall bioavailability significantly.

Distribution:
Sumatriptan exhibits a moderate volume of distribution at approximately 2.4 L/kg, indicating extensive distribution into body tissues. It is about 14–21% protein-bound in plasma, which allows for active circulation but limits extensive binding-related drug interactions. Sumatriptan readily crosses the blood-brain barrier, reaching central nervous system sites critical for its antimigraine effects. It also distributes into nasal mucosa when administered intranasally, facilitating local and systemic action. The drug’s distribution characteristics contribute to its ability to act on cranial blood vessels and trigeminal nerve terminals.

Metabolism:
Sumatriptan undergoes extensive first-pass metabolism primarily in the liver. The principal pathway is oxidative deamination mediated by monoamine oxidase A (MAO-A), which converts sumatriptan to an inactive indole acetic acid metabolite. Minor metabolism occurs through other hepatic enzymes. Because MAO-A metabolizes sumatriptan, concurrent use of MAO inhibitors can lead to increased plasma concentrations and heightened risk of adverse effects, and thus is contraindicated within 14 days of MAOI administration. The metabolites are pharmacologically inactive and do not contribute to therapeutic or adverse effects.

Elimination:
The elimination half-life of sumatriptan is approximately 2 hours after oral administration, reflecting rapid clearance. Renal excretion is the primary route of elimination for sumatriptan and its metabolites, with roughly 60% excreted in urine as metabolites and less than 5% as unchanged drug. Fecal elimination accounts for about 40%. Clearance is reduced in patients with severe hepatic or renal impairment, necessitating cautious use with appropriate dose adjustments. The quick elimination supports use for episodic treatment without drug accumulation from repeated doses within 24 hours.

Dosage Forms

Available Dosage Forms:
- Oral tablets: 25 mg, 50 mg, 100 mg
- Nasal spray: 5 mg, 10 mg, 20 mg per actuation
- Nasal powder/capsule with Onzetra Xsail breath-powered delivery device: 11 mg per nostril
- Subcutaneous injection: 4 mg and 6 mg autoinjector or single-use vial

Dosages for Adults and Adolescents:
- Oral tablets: Initial dose 25 mg, 50 mg, or 100 mg once at onset of migraine symptoms. A second dose may be taken at least 2 hours after the first dose if needed, with a maximum daily dose of 200 mg. Usually not recommended to treat more than 4 migraine attacks per month without medical reassessment.
- Nasal spray: Single spray in one nostril delivering 5 mg or 20 mg; 10 mg dose achieved by administering 5 mg spray in each nostril. Second dose may be taken after 2 hours as needed, maximum 40 mg per 24-hour period.
- Nasal powder (Onzetra Xsail): One 11 mg dose delivered into each nostril once per migraine attack. Maximum is two doses per 24 hours, with doses separated by at least 2 hours.
- Injection: 6 mg subcutaneous injection initially; if some relief is seen, a second 6 mg dose may be given at least 1 hour later. Maximum total dose per 24 hours is 12 mg. Lower 4 mg dose considered if side effects limit tolerability.

Specific Patient Populations:
- Pediatric Use: Safety and efficacy in patients under 18 years not established; use not approved.
- Geriatrics: Dose adjustment not specifically required but cautious use recommended owing to increased sensitivity.
- Hepatic Impairment: Use with caution; lower doses may be necessary due to reduced metabolism.
- Renal Impairment: Cautious use advised; elimination may be slower.
- Pregnancy and Breastfeeding: Use only if clearly needed; breastfeeding not recommended within 12 hours after dosing; milk pumped during this period should be discarded.

Clinical Guidelines:
Sumatriptan should be administered at the early onset of migraine with aura or without aura. It is not effective for preventing migraine attacks or for tension-type headaches. Dosage should be individualized based on patient response and tolerability.

Mechanism Of Action

Sumatriptan is a selective agonist at serotonin 5-HT1B and 5-HT1D receptors. These G-protein coupled receptors are located on intracranial blood vessels and on nerve terminals of the trigeminal sensory nerves, which play a central role in the pathophysiology of migraine headaches.

Upon binding to the 5-HT1B receptors located primarily on cranial blood vessels, sumatriptan induces vasoconstriction of the dilated extracerebral arteries. This vasoconstriction counteracts the abnormal vasodilation thought to contribute to migraine pain, thus reducing the headache.

Additionally, activation of 5-HT1D receptors on trigeminal nerve endings inhibits the release of pro-inflammatory neuropeptides such as calcitonin gene-related peptide (CGRP), substance P, and neurokinin A. These neuropeptides promote neurogenic inflammation and vasodilation, exacerbating migraine symptoms. By reducing their release, sumatriptan decreases neurogenic inflammation and peripheral sensitization.

The combined vasoconstriction and inhibition of neuropeptide release effectively suppress the transmission of pain signals within trigeminal pathways and reduce the central sensitization associated with migraine attacks. Clinically, this results in relief from headache pain, nausea, photophobia, and phonophobia.

Compared to other triptans, sumatriptan has relatively rapid onset of action, especially with subcutaneous injection, making it effective for aborting acute migraine attacks swiftly. Research supports its efficacy and safety across various formulations, with numerous clinical trials validating its role as a first-line acute migraine therapy.

Pharmacological Actions

Selective 5-HT1B/1D receptor agonist activity leading to cranial vasoconstriction
Inhibition of release of neuropeptides involved in neurogenic inflammation such as CGRP and substance P
Reduction of peripheral and central sensitization in trigeminal pain pathways
Rapid attenuation of migraine-associated symptoms including headache, nausea, photophobia, and phonophobia
Abortive antimigraine action with no efficacy in migraine prophylaxis
Minimal central nervous system psychotropic effects due to selective receptor targeting
Dose-dependent pharmacodynamic effects on cerebral blood vessels
Effective via multiple routes: oral, nasal, and subcutaneous injection
No significant platelet aggregation effects despite serotonin receptor activity
Lacks significant interaction with adrenergic or dopaminergic pathways
Limited impact on systemic blood pressure at therapeutic doses
Reduces migraine-induced neurogenic inflammation and plasma protein extravasation
Induces constriction predominantly in extracranial rather than intracerebral vessels

Therapeutic Or Clinical Uses

Acute treatment of migraine headaches with or without aura in adults
Acute treatment of cluster headache attacks in adults (subcutaneous injection only)
Management of migraine symptoms including headache pain, nausea, sensitivity to light and sound
Rapid abortive therapy to mitigate severity and duration of migraine episodes
Alternative migraine therapy for patients who do not tolerate or respond to NSAIDs
Treatment option when migraine diagnosis is clearly established and confirmed
Off-label uses in refractory migraine cases as adjunct therapy
Emergency treatment of severe acute migraine in clinical settings
Reduction of migraine-associated disability through symptom control
Use in patients with episodic migraine with clear attack patterns
Non-preventive agent, not indicated for migraine prophylaxis
Therapeutic option to reduce frequency of emergency room visits due to migraines
Combination therapy with other supportive migraine medications under medical supervision
Treatment of acute migraine in patients where oral administration is limited (e.g., nausea/vomiting) via nasal or injection routes

Side Or Adverse Effects

Chest pain or tightness, pressure or heaviness in chest, throat, or jaw
Numbness, tingling, or burning sensations especially in extremities or face
Dizziness, somnolence, weakness, or fatigue
Unusual or unpleasant taste following nasal administration
Nasal discomfort, burning, or irritation after nasal spray or powder use
Runny or congested nose following nasal application
Serious hypersensitivity reactions including hives, facial swelling, or breathing difficulties
Severe chest pain with potential cardiovascular compromise
Arrhythmias or irregular heartbeats
Seizures or convulsions
Severe or sudden headache with neurological signs indicative of stroke
Gastrointestinal symptoms such as severe stomach pain or bloody diarrhea
Peripheral vascular ischemia symptoms such as coldness, color changes, muscle cramps in limbs
Serotonin syndrome manifestations: agitation, hallucinations, fever, muscle rigidity, tremors
Rebound headaches or medication-overuse headache with frequent use

Precautions

Use only if migraine diagnosis is confirmed; do not treat other headache types with sumatriptan
Avoid use in patients with history of ischemic heart disease or stroke
Caution in patients with risk factors for coronary artery disease including diabetes, hypertension, hyperlipidemia, age over 40 (men), smoking, or family history
Avoid coadministration with monoamine oxidase inhibitors or within 14 days of their discontinuation
Monitor for signs of serotonin syndrome when used with other serotonergic drugs such as SSRIs, SNRIs, or triptans
Exercise caution in hepatic or renal impairment due to altered drug metabolism and clearance
Avoid use during pregnancy unless benefits outweigh risks; breastfeeding mothers should avoid nursing for 12 hours post-dose
Do not exceed recommended maximum daily dose to prevent serious adverse effects
Avoid use within 24 hours of other migraine medications including other triptans or ergot derivatives
Use with caution in patients with uncontrolled hypertension
Do not initiate therapy in patients with atypical or prolonged headaches without thorough assessment
Instruct patients to report any chest pain or cardiovascular symptoms immediately
Monitor elderly patients closely although no specific dosage adjustment is universally required
Avoid driving or hazardous activities until individual response to drug therapy is established
Assess cardiovascular status prior to therapy initiation in at-risk populations

Warnings

Contraindicated in patients with uncontrolled high blood pressure or severe cardiovascular diseases
Do not administer to patients with history of cerebrovascular events including stroke or transient ischemic attacks
Avoid use in patients with peripheral vascular disease or circulation problems
Risk of serious serotonin syndrome when combined with other serotonergic agents
Not to be used in treatment of headache types other than migraine as diagnosis must be clear
Avoid use within 24 hours before or after administration of other migraine therapies including ergot derivatives and other triptans
Use with caution in patients with Wolff-Parkinson-White syndrome or other conduction abnormalities
Serious hypersensitivity and anaphylactic reactions have been reported
Possible risk of myocardial infarction, arrhythmias, or chest pain requiring emergency evaluation
Potential for rebound or medication-overuse headaches with frequent usage
Increased risk of adverse vascular events in patients with significant cardiovascular risk factors
Pregnancy category risk not established; weigh risks and benefits
Breastfeeding contraindicated within 12 hours post-dose due to drug excretion in milk
Patients should be warned against excessive or frequent dosing beyond recommended limits
Do not use sumatriptan for migraine prophylaxis

Contraindication

Hypersensitivity to sumatriptan or any component of the formulation
History of ischemic heart disease including angina pectoris or myocardial infarction
Uncontrolled hypertension or cerebrovascular syndrome (stroke, transient ischemic attack)
Peripheral vascular disease or significant circulation problems
Wolff-Parkinson-White syndrome or other significant cardiac conduction abnormalities
Severe hepatic impairment
Concomitant or recent use (within 14 days) of monoamine oxidase inhibitors (MAOIs)
Use with ergotamine-containing drugs or other 5-HT1 agonists within 24 hours
Treatment of hemiplegic or basilar migraine
Prior history of stroke or transient ischemic attacks
Patients with basilar or hemiplegic migraine
Patients with a history of ischemic bowel disease
Severe renal impairment requiring close medical supervision
Use in pediatric patients under 18 years of age
Use in tension-type headache or headache types other than migraine

Drug Interactions

Concomitant use with monoamine oxidase inhibitors (MAOIs) can increase sumatriptan plasma levels and risk of toxicity
Increased risk of serotonin syndrome when combined with SSRIs, SNRIs, tricyclic antidepressants, or other serotonergic drugs
Potential additive vasoconstrictive effects with ergot-containing drugs such as ergotamine, dihydroergotamine, methysergide
Interactions with other triptans require at least 24-hour interval between doses to avoid increased adverse effects
Co-administration with stimulant medications or opioids may increase serotonergic adverse effects
Herbal supplements with serotonergic properties like St. John's Wort may enhance serotonin syndrome risk
CYP450 metabolism interactions are minimal but caution advised with MAO-A inhibitors
Use with other migraine drugs should be separated by adequate intervals to prevent cumulative vasoconstrictive effects
Fluoxetine, fluvoxamine, paroxetine, sertraline, and other antidepressants increase serotonergic activity
Linezolid and methylene blue increase serotonin toxicity risk when used concurrently
Concurrent use with triptans or ergotamine-containing drugs increases risk of vasospastic reactions
Avoid simultaneous use with drugs that prolong QT interval without cardiology supervision
Alcohol may exacerbate central nervous system side effects
Drug interactions may enhance cardiovascular adverse effects such as hypertension or arrhythmias
Close monitoring recommended when used with other agents affecting cardiovascular or central nervous systems

Preparations Of The Drug

Sumatriptan oral tablets available in 25 mg, 50 mg, and 100 mg strengths
Sumatriptan nasal spray formulations delivering 5 mg, 10 mg, or 20 mg doses per administration
Subcutaneous injection supplied as 4 mg and 6 mg doses via autoinjector pens or single-use vials
Onzetra Xsail nasal powder preparation delivered as an 11 mg breath-powered capsule per nostril
Zembrace SymTouch is a ready-to-use autoinjector for subcutaneous administration
Tosymra nasal spray using a proprietary formulation for rapid drug delivery
Alsuma injection autoinjector device for subcutaneous administration
Generic formulations of sumatriptan available in all major dosage forms
Combination inhaler systems to enhance nasal delivery and absorption
Patient-friendly packaging with detailed instructions for use for various dosage forms
Formulations designed for rapid onset of action tailored to migraine symptom relief
Sterile injectable solutions for parenteral administration
Powder blends optimized for nasal mucosal absorption
Oral tablet coatings designed to facilitate swallowing and absorption
Dosing devices calibrated to deliver precise quantities for consistent therapeutic effect